PT3752190T - Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 - Google Patents

Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20

Info

Publication number
PT3752190T
PT3752190T PT197098189T PT19709818T PT3752190T PT 3752190 T PT3752190 T PT 3752190T PT 197098189 T PT197098189 T PT 197098189T PT 19709818 T PT19709818 T PT 19709818T PT 3752190 T PT3752190 T PT 3752190T
Authority
PT
Portugal
Prior art keywords
antibodies
cancer regimen
regimen
cancer
Prior art date
Application number
PT197098189T
Other languages
English (en)
Original Assignee
Forty Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven Inc filed Critical Forty Seven Inc
Publication of PT3752190T publication Critical patent/PT3752190T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT197098189T 2018-02-12 2019-02-11 Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20 PT3752190T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862629340P 2018-02-12 2018-02-12
US201862678468P 2018-05-31 2018-05-31
US201862743060P 2018-10-09 2018-10-09
US201862743875P 2018-10-10 2018-10-10

Publications (1)

Publication Number Publication Date
PT3752190T true PT3752190T (pt) 2022-11-18

Family

ID=65718081

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197098189T PT3752190T (pt) 2018-02-12 2019-02-11 Regime anticancerígeno usando anticorpos anti-cd47 e anti-cd20

Country Status (12)

Country Link
US (2) US11891450B2 (pt)
EP (2) EP4129336A1 (pt)
JP (2) JP7343528B2 (pt)
KR (1) KR20200119834A (pt)
CN (1) CN111699005A (pt)
AU (1) AU2019218271A1 (pt)
CA (1) CA3090489A1 (pt)
ES (1) ES2927305T3 (pt)
PL (1) PL3752190T3 (pt)
PT (1) PT3752190T (pt)
SI (1) SI3752190T1 (pt)
WO (1) WO2019157432A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102472087B1 (ko) 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
PL3752190T3 (pl) 2018-02-12 2022-11-07 Forty Seven, Inc. „schemat przeciwnowotworowy z wykorzystaniem przeciwciał anty-cd47 i anty-cd20
US20220119523A1 (en) * 2019-02-08 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
CA3141130A1 (en) * 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
WO2021046216A1 (en) * 2019-09-03 2021-03-11 Arch Oncology, Inc. Methods for identifying biomarkers to predict treatment response
RS65480B1 (sr) 2019-09-18 2024-05-31 Lamkap Bio Alpha AG Bispecifična antitela protiv ceacam5 i cd3
AU2020374947A1 (en) * 2019-10-31 2022-03-31 Forty Seven, Inc. Anti-CD47 and anti-CD20 based treatment of blood cancer
TW202134280A (zh) * 2019-12-05 2021-09-16 美商索倫多醫療公司 包含抗cd47抗體與腫瘤靶向抗體之組合物及方法
AU2021205144A1 (en) * 2020-01-09 2022-08-25 Innovent Biologics (Suzhou) Co., Ltd. Application of combination of anti-CD47 antibody and anti-CD20 antibody in preparation of drugs for preventing or treating tumors
WO2021157650A1 (ja) * 2020-02-05 2021-08-12 カルナバイオサイエンス株式会社 抗がん剤組成物
WO2021219092A1 (en) * 2020-04-30 2021-11-04 I-Mab Biopharma Co., Ltd. Pharmaceutical compositionscontaining anti-cd47 antibodies
CN112578117B (zh) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 抗体组合物及其筛查移植后淋巴细胞增殖性疾病的应用
WO2024010842A1 (en) * 2022-07-07 2024-01-11 The Board Of Trustees Of The Leland Stanford Junior University Targeting cells with a combination of cxcr2 inhibition and cd47 blockade

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
WO2004032828A2 (en) 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
US7601355B2 (en) 2005-06-01 2009-10-13 Northwestern University Compositions and methods for altering immune function
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2682266A1 (en) 2007-03-28 2008-10-09 Biogen Idec Inc. Treatment of hodgkins lymphoma
WO2009091547A1 (en) 2008-01-15 2009-07-23 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT3056514T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação de fagocitose mediada por cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011034969A1 (en) 2009-09-15 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
EA201890907A1 (ru) 2009-11-30 2020-04-30 Янссен Байотек, Инк. МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
RS60606B1 (sr) 2012-01-17 2020-08-31 Univ Leland Stanford Junior Reagensi sirp-alfa visokog affiniteta
PT3575326T (pt) 2012-12-17 2022-05-30 Pf Argentum Ip Holdings Llc Tratamento de células de doença cd47+ com fusões sirp alfa-fc
BR112015018851A2 (pt) 2013-02-06 2017-07-18 Inhibrx Llc anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
PT2970493T (pt) * 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
CN103665165B (zh) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
SG11201607143UA (en) 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN106535914B (zh) 2014-08-08 2021-08-27 Alx 肿瘤生物技术公司 SIRP-α变体构建体及其用途
RS62151B1 (sr) 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
KR20180083895A (ko) 2015-12-11 2018-07-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Cd47 및 egfr의 이중 표적화를 이용한 암의 치료
KR102472087B1 (ko) 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
KR20180102628A (ko) 2016-01-21 2018-09-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 면역조절제의 조합물에 의한 암의 치료
EP3442593A4 (en) 2016-04-15 2020-01-01 Trillium Therapeutics Inc. STIMULATION OF MACROPHAGES IN THERAPY BY CD47 BLOCKING
EP3442578B1 (en) * 2016-04-15 2022-02-09 The Board of Trustees of the Leland Stanford Junior University Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
CN106084052B (zh) 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
EP4194470A1 (en) 2017-10-18 2023-06-14 Forty Seven, Inc. Treatment of ovarian cancer with anti-cd47 and anti-pd-l1
KR20200068730A (ko) 2017-10-18 2020-06-15 포티 세븐, 인코포레이티드 항-cd47 작용제-기초된 난소암 요법
PL3752190T3 (pl) 2018-02-12 2022-11-07 Forty Seven, Inc. „schemat przeciwnowotworowy z wykorzystaniem przeciwciał anty-cd47 i anty-cd20

Also Published As

Publication number Publication date
ES2927305T3 (es) 2022-11-04
CA3090489A1 (en) 2019-08-15
JP2023115349A (ja) 2023-08-18
PL3752190T3 (pl) 2022-11-07
JP2021515805A (ja) 2021-06-24
CN111699005A (zh) 2020-09-22
JP7343528B2 (ja) 2023-09-12
EP3752190B1 (en) 2022-07-06
AU2019218271A1 (en) 2020-09-10
US20190248915A1 (en) 2019-08-15
SI3752190T1 (sl) 2022-11-30
WO2019157432A1 (en) 2019-08-15
US11891450B2 (en) 2024-02-06
US20240218077A1 (en) 2024-07-04
EP4129336A1 (en) 2023-02-08
WO2019157432A8 (en) 2020-06-25
KR20200119834A (ko) 2020-10-20
EP3752190A1 (en) 2020-12-23

Similar Documents

Publication Publication Date Title
SI3752190T1 (sl) Shema zdravljenja proti raku z uporabo protiteles proti CD47 in proti CD20
IL272330A (en) Anti-CD47 antibodies and uses thereof
ZA202105676B (en) Anti-trem2 antibodies and related methods
HK1253305A1 (zh) Cd123 抗體及其綴合物
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and their combinations
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
IL290457A (en) Antibodies and their conjugates
IL267129A (en) New T-cell receptors and immunotherapy using them
RS62498B1 (sr) T-ćelijski receptori i imunoterapija u kojoj se koriste
IL271222A (en) Dosing regimens for anti-tim-3 antibodies and their uses
ZA201900664B (en) T cell receptors and immune therapy using the same
HK1259455A1 (zh) 抗原受體及其用途
EP3374382A4 (en) BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
EP3507369C0 (en) ANTI-CD20 ANTIBODIES
IL266059A (en) Anti-rankl antibodies and their uses
IL264855B1 (en) T-cell receptors and immunotherapy using them
IL267131A (en) Novel t cell receptors and immune therapy using the same